Bone Therapeutics, SA, an international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, has successfully closed a Series D funding which raised 7.7 million Euros from current investors and the Walloon Region. The company is headquartered at the Biopôle of Gosselies, which is south of Brussels, Belgium.
The funds raised will be used to accelerate the development of Bone Therapeutics’ bone cell therapy pipeline, as well as sustain the ongoing Phase III clinical trials for its lead product PREOB. PREOB is an autologous bone cell therapy product which is in Phase III clinical trials for the treatment of osteonecrosis and non-union fractures. The company’s cell therapy approach seeks to significantly improve upon current standard of care for bone diseases. All Bone Therapeutics’ cell products are osteoblastic (i.e., bone-forming) and require a minimally invasive administration technique, avoiding the need for surgery.
